Navigation Links
Thyroid surgery safe for older patients, study finds
Date:10/19/2009

e enough to impact swallowing and/or breathing. While some of these larger growths are very obvious, those that grow downward into the chest or toward the back can be harder to detect. In older patients, many of the growths likely have been there a while, Dr. Seybt says.

Depending on the size of the growth in patients, surgeons at MCG and the VA will use one of three different approaches. These include a standard, several-inch incision at the base of the neck for the largest growth as well as include minimally invasive thyroidectomy, in which surgeons work through an incision about half the size of the norm, and an endoscopic approach, in which video monitoring and a thin, ultrasonic scalpel reduce incision size another half.

Dr. David Terris, chair of the Department of Otolaryngology-Head and Neck Surgery in the MCG School of Medicine and a pioneer of the minimally invasive approaches, showed in the March 2006 issue of Laryngoscope that the newer, minimally invasive approaches, which reduce the incision size and recovery time, could be used safely in most patients. Dr. Terris is corresponding author on the current study.

Dr. Terris and Sunny Khichi, a senior medical student at MCG, are study co-authors.


'/>"/>

Contact: Toni Baker
tbaker@mcg.edu
706-721-4421
Medical College of Georgia
Source:Eurekalert  

1

GOOD

Page: 1 2 3

Related medicine news :

1. PREOS(R) Granted U.S. Orphan Drug Status for Treatment of Hypoparathyroidism
2. Fluoride Damages the Thyroid, Report Shows
3. Thyroid Test Wont Help Pregnant Mom, Baby
4. Better detection accounts for increase in cases of thyroid cancer
5. Thyroid treatment no quick fix for weight loss in children
6. Early detection critical in treating pediatric thyroid cancer
7. Mailman School PH study finds increase in thyroid diseases risk from exposure at Chernobyl
8. Combination of Thyroid Medicines Not Necessary
9. Newly discovered role of thyroid hormone during pregnancy
10. Does artificial intelligence help clinicians to recognize atrophic gastritis with thyroid disease?
11. Thyroid Hormone Could One Day Treat Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Thyroid surgery safe for older patients, study finds
Thyroid surgery safe for older patients, study finds
(Date:12/14/2009)... Americold Realty Trust ("Americold") announced today that it has ... U.S. Securities and Exchange Commission (the "SEC") relating to ... The number of shares to be offered and the ... determined. The common shares to be sold in this ... ,, The joint book-running managers of the offering will ...
(Date:12/14/2009)... -- Aflac Incorporated announced today that it has ... notes with a coupon of 6.9%. The notes ... to yield 6.984%. The company anticipates using the ... general corporate purposes. ,, Commenting on the pricing ... Chief Financial Officer Kriss Cloninger III commented: "This ...
(Date:12/14/2009)... -- Tough Enough To Wear Pink(TM) (TETWP), the ... its fifth anniversary at the signature Tough Enough ... Finals Rodeo (Wrangler NFR) in Las Vegas. While ... cowboys, the support of the western industry and ... sported pink shirts, hats, bracelets and more. ...
(Date:12/14/2009)... 13 years under government controlled health care, before moving to the ... engagements and in his new book, Health Reform: The End of ... a system and its threat to real health care! , ... ... a diagnostic radiologist from Minnesota, warns Americans not to sell out ...
(Date:12/14/2009)... Dec. 14 Skilled nursing facilities (SNFs) in ... in order to deal with a 92 percent increase ... from $6.25 to $12.01 per bed per day, scheduled ... average facility will pay an additional $17,520 to the ... total tax of $438,365 yearly. ,, Nearly 96 percent ...
Breaking Medicine News(10 mins):Health News:Americold Realty Trust Files Registration Statement for Proposed Initial Public Offering 2Health News:Aflac Incorporated Prices $400 Million of 30-Year Senior Notes 2Health News:Aflac Incorporated Prices $400 Million of 30-Year Senior Notes 3Health News:Aflac Incorporated Prices $400 Million of 30-Year Senior Notes 4Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 2Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 3Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 4Health News:Canadian Doctor Warns Against Government-Run, Socialized Medicine and its Threat to Health Care and Freedom in America 2Health News:Survey Shows Tax Increase Forcing Ohio Skilled Nursing Facilities to Make Cuts 2Health News:Survey Shows Tax Increase Forcing Ohio Skilled Nursing Facilities to Make Cuts 3
... ArlenGroup, the leading provider,of employee benefit consulting and ... law firms, announces the expansion of its West ... Rees LLP has entered the,Consortium beginning January 1, ... LLP, and Wilson Sonsini Goodrich & Rosati PC ...
... from the Center for Bioinformatics at Peking University ... atlas underlying drug addiction and identified five molecular ... This novel paper appears in PLoS Computational Biology ... a serious worldwide problem with strong genetic and ...
... workers or those with narcolepsy, scientists say , FRIDAY, Jan. ... orexin-A may be key to undoing the negative mental effects ... Orexin-A is a peptide (a kind of protein) made in ... the Wake Forest University School of Medicine in Winston-Salem, N.C. ...
... key articles of interest to caregivers and those who suffer ... of leukemia, and how different societies have looked at the ... describe new research based on identifying the many variations ... sub-types more precisely , show ...
... Highest Honor for Organizational Performance Excellence, ANN ... (MQC) announces Oakwood Healthcare, Inc. as a 2007 ... Award is the highest honor for,organizational performance excellence ... review by a team of examiners who perform ...
... The Michael J. Fox,Foundation has committed up to ... therapeutic to treat Parkinson,s disease by reducing expression,of ... by Matt Farrer,PhD, of Mayo Clinic Jacksonville (Florida) ... and Clinical Center will work,to optimize a small ...
Other Medicine News:Health News:Gordon & Rees LLP Joins ArlenGroup-CIGNA Health Care Purchasing Consortium 2Health News:Gordon & Rees LLP Joins ArlenGroup-CIGNA Health Care Purchasing Consortium 3Health News:Protein Nasal Spray Revives Sleep-Deprived Monkeys 2Health News:Michigan Quality Council (MQC) Names Oakwood Healthcare Inc. 2007 State Quality Award Recipient 2Health News:Michael J. Fox Foundation Commits up to $3.8 Million to Develop Gene Silencing Neuroprotective Treatment for Parkinson's Disease 2Health News:Michael J. Fox Foundation Commits up to $3.8 Million to Develop Gene Silencing Neuroprotective Treatment for Parkinson's Disease 3
(Date:12/14/2009)... Dec. 14 In response to an ... 2009, in which the Agency recommended that healthcare ... (SS1) sterile processing system, hospitals throughout the U.S. ... alternatives to that product. According to the FDA, ... SS1 that may affect the safety or the ...
(Date:12/14/2009)... Dec. 14 The board of directors of ... today declared a dividend for the first quarter of ... ,, The dividend is payable March 10, ... business on ,, February 12, 2010. ,, Lilly, ... of pharmaceutical products by applying the latest research from ...
(Date:12/14/2009)... Zargis Medical Corp., a majority-owned subsidiary of Speedus ... from Siemens Corporate Research (NYSE: SI ... its award-winning Zargis Cardioscan(TM) system on Amazon.com, America,s ... Bluetooth®-enabled electronic stethoscope were jointly named Popular ... the Year." Cardioscan is the world,s first ...
Breaking Medicine Technology:ECRI Institute Issues Steris System 1 High Priority Alert and Recommendations: Free Guidance to Help Hospitals Map out Transition to Alternative Reprocessing Methods 2ECRI Institute Issues Steris System 1 High Priority Alert and Recommendations: Free Guidance to Help Hospitals Map out Transition to Alternative Reprocessing Methods 3Zargis Cardioscan 'The Intelligent Stethoscope' Now Available on Amazon.com 2Onyx Pharmaceuticals to Present at the Credit Suisse 18th Annual Healthcare Conference 14723 1Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 5994 1Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 5994 2Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 5994 3Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 5994 4Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 5994 5Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 5994 6Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 5994 7Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 5994 8Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 5994 9Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 5994 10Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 5994 11Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 5994 12Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 5994 13Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 5994 14Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 5994 15Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 5994 16Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 5994 17Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 5994 18Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent 5994 19NeoStem Inc Names Edward Geehr M D to Board of Directors 3B Biotechnology Executive Brings Scientific and Business Experience in Global Operations 5991 1NeoStem Inc Names Edward Geehr M D to Board of Directors 3B Biotechnology Executive Brings Scientific and Business Experience in Global Operations 5991 2NeoStem Inc Names Edward Geehr M D to Board of Directors 3B Biotechnology Executive Brings Scientific and Business Experience in Global Operations 5991 3
... Pa., May 30 Wyeth,Pharmaceuticals, a division ... announced the,initiation of the INTORACT (INvestigation of ... randomized, open-label, phase 3b,study comparing TORISEL(R) (temsirolimus) ... first-line treatment of patients,with advanced renal cell ...
... of safety and tolerability, as well ... trials -, ROCKVILLE, Md., May 30 Human ... it has initiated dosing in a Phase,1 clinical trial ... IAP,inhibitor, HGS1029, as monotherapy in patients with advanced solid ...
Other Medicine Technology:Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer 2Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer 3Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer 4Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer 5Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer 6Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors 2Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors 3Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors 4
Subretinal Fluid Cannula, Straight; 20g (0.90) x 1-1/2" (38mm); 12mm Flexible Tubing Extends 6mm Beyond Tip....
Micro Vitreoretinal Cannula; Angled; 20g (0.90) x 1" (25mm); Tip Extension: 3mm, 32g (0.23); Angled at 65°, 1mm from Tip....
...
...
Medicine Products: